Survey and Follow-up of the Treatment Adherence and Medication Habits of Early Breast Cancer Patients on Adjuvant Hormonal Therapy With the Aromatase Inhibitor Arimidex
Observational Model: Cohort, Time Perspective: Prospective
Percent of patients remaining adherent to therapy with Arimidex
Every 3 months
Zsolt Horvath, M.D., Ph.D.
Hungarian National Institute of Oncology
Hungary: National Institute of Pharmacy